Livestock production, antimicrobial resistance and institutional risk

From livestock output to public health

Livestock farming connects food production, employment, trade, animal welfare, veterinary services and human health. The relevant risk is not the mere presence of animals in a productive system. It arises from interactions among animal health, the density and movement of herds, disease surveillance, sanitation, management decisions and antimicrobial exposure. Different production models present different combinations of hazards and preventive capacity.

The biological and economic mechanism

Antimicrobials can be necessary to treat bacterial infections in animals. Their use also creates selection pressure that can favor resistant microorganisms. Resistance is a process in microbial populations; it should not be represented as an animal or person becoming resistant. Resistant organisms and resistance determinants can circulate through linked human, animal and environmental settings. The relative contribution of each pathway varies by organism, place and exposure and cannot be inferred from national antibiotic sales alone.

WHO identifies antimicrobial resistance as a major public-health threat, with consequences for the safety of surgery and other modern treatments. Higher treatment costs, prolonged illness, mortality and lost productivity create economic effects beyond the livestock operation. [1]

Incentives and unequal capacities

A producer faces costs from veterinary visits, housing changes, lower stocking density in some settings, disease surveillance and losses following infection. Prevention can reduce the need for treatment, but the optimal investment depends on farm size, veterinary access, financing and enforcement. A policy limited to prohibiting drugs without affordable veterinary alternatives may produce unintended animal-welfare and compliance problems.

Regulatory systems must distinguish therapeutic use, prophylaxis under defined conditions and use for non-therapeutic production purposes. They must also separate antimicrobial classes, animal species and exposure measures. International comparisons require compatible surveillance definitions.

Disease preparedness and trade

High animal mobility can connect distant production sites, markets and processing facilities. When infectious disease emerges, consequences can include animal mortality, movement restrictions, interruptions to slaughter and exports, and household income losses. Monitoring therefore combines veterinary disease surveillance, laboratory capability, timely notification and trade governance. Surveillance failures can stem from weak budgets, limited diagnostics or incentives to conceal outbreaks.

Integrated institutional framework

A comparative study should pair data on antimicrobial use by species and class with microbiological resistance surveillance, farming-system characteristics and human clinical outcomes. Simple cross-country correlations are insufficient because diagnostics, reporting and antimicrobial access differ.

Competing interpretations and tests

One hypothesis is that intensive production necessarily increases population antimicrobial resistance. A competing hypothesis is that veterinary access, preventive practices and prescribing governance explain more variation than herd density alone. Both are testable only with organism-specific observations, consistent surveillance and exposure data. Veterinary and human medical prescribing also need to be measured separately.

For economic evaluation, measure the costs of prevention alongside expected losses from illness, treatment, mortality and trade interruptions. Distributional analysis should include small producers, agricultural workers, consumers and national public-health systems rather than treating aggregate meat output as an adequate welfare measure.

Chemical and biological security boundaries

Food-chain and animal-health infrastructure can be deliberately disrupted, but an outbreak is not evidence of an intentional biological attack. Attribution requires independent epidemiological and forensic findings and documented investigative procedures. Chemical and biological weapons governance belongs to distinct treaty regimes; the OPCW implements the Chemical Weapons Convention, while the Biological Weapons Convention has a different institutional and verification architecture. [2, 3]

The strategic issue is the capacity to prevent, identify and absorb animal and human health shocks while maintaining food supply and lawful international trade. The quality of disease surveillance, access to veterinary services and public-sector coordination is as consequential as farm-level technical choices.

Agricultural modernization and the changing geography of disease

Animal domestication altered nutrition, labor organization, transport and the relationship between human settlements and other species. The historical expansion of cities also created opportunities for infectious agents to circulate where populations, food waste and water systems were concentrated. Such long-run relationships cannot be reduced to an assertion that livestock production itself caused particular epidemics: pathogen identity, historical ecology, population density, sanitation and trade routes matter. Advances in refrigeration, clinical microbiology, slaughter inspection and veterinary vaccination later changed risk without removing the economic need for animal protein in many places.

Modern livestock systems range from small mixed farms to high-volume specialist operations. Intensification may concentrate susceptible animals and magnify the consequences of weak biosecurity, yet industrial investment may also fund better veterinary services, enclosed transport, record keeping, controlled processing and diagnostic laboratories. Poorly supervised extensive systems can carry hazards of their own, including interactions at wildlife and grazing interfaces. Valid comparisons require species, region, infection, preventive capacity, contact patterns and production denominators. Neither animal density nor the label 'industrial' is a substitute for those observations.

Changes in food markets can transmit a localized disease shock internationally. A disease that reduces animal production can raise prices, change import demand, close markets and undermine rural income without causing human infection. A different hazard may produce foodborne illness among consumers or occupational exposure among workers. These are distinct pathways and should be reported separately, rather than assigned a shared undifferentiated 'zoonotic' effect.

What the global surveillance evidence says

The WHO's Global antibiotic resistance surveillance report 2025, issued on 13 October 2025, draws on more than 23 million bacteriologically confirmed cases in selected infection and pathogen categories. Data for 2023 were submitted by 104 countries; 110 countries supplied information at least once between 2016 and 2023. The 23 million number is a surveillance dataset size, not a count of antibiotic-resistant cases or deaths. Nor are country participation counts prevalence estimates. [4]

These bars have different observation windows and must not be interpreted as a time-series improvement of six countries. The gap illustrates why the coverage and completeness of surveillance data should be presented beside any comparison of resistance patterns. Differences in antibiotic access, ability to conduct microbiological tests and selection of patients for culture can shift the observed fraction of resistant isolates without equivalent changes in community incidence.

The WOAH 2025 animal antimicrobial-use release reported data covering approximately 71% of the world's animal biomass in its ninth reporting assessment and described a decline of 5% in reported use in its comparison set. Neither figure implies that 71% of all farms submitted records, that the remaining biomass used no antibiotics, or that antimicrobial resistance itself fell by 5%. The reporting universe and comparability limits need to be carried forward in the analysis. [5]

The second value is the mathematical complement of the reported 71%, not an independently measured indicator. Coverage does not imply random sampling or full comparability among reporting countries; larger producers and countries with functioning administrative systems may be disproportionately represented.

Selection pressure does not explain every transmission chain

Resistance may emerge or be selected under antimicrobial exposure in human medicine, veterinary practice and some environmental conditions. Transmission then depends on the microbial species, genetic mechanism, sanitation, food preparation, occupational contact and healthcare infection control. A resistance gene detected in an animal sample and a gene detected in a hospital sample do not alone establish direction of transmission. A defensible attribution would require organism-specific study design, genomic or epidemiological relationships where available and control of competing sources.

The One Health Quadripartite—FAO, WHO, WOAH and UNEP—issued integrated surveillance guidance in January 2026. It emphasizes combined observation of antimicrobial use and resistance across sectors, designed around national capacities. The guidance is not a universal claim that every sector contributes the same fraction of human illness. [6]

In surveillance, absence of detected resistance can indicate either low prevalence or low test sensitivity and coverage. Countries reporting more resistance may have better laboratory networks and denominator information. Analysts should present sampling proportions, time periods, culture indications, isolate counts and uncertainty intervals where possible, rather than ranking health systems solely by the crude fraction of resistant samples.

The production and treatment decisions of individual farms

A farm operator makes choices under uncertain infection risk and observable financial constraints. A veterinary visit can incur transport costs; diagnosis may require samples and delays; better ventilation or building redesign requires capital; purchasing vaccinated stock can change cash-flow timing. A producer who cannot finance preventive measures may use therapeutic products later, with higher animal losses. These choices create an economic distinction between changing incentives and issuing prohibitions.

The social gains from prevention can exceed the private benefits when reduced infection or resistance also protects neighboring farms and people. Such spillovers justify examining veterinary extension, vaccination programs, cooperative diagnostics and surveillance financing. They do not automatically justify one specific instrument, since the size of external effects varies by pathogen and production system. Governments need to compare preventive investment with enforcement costs, animal welfare and risks of unauthorized medicine markets.

Where disease is already present, withholding necessary treatment can harm animals and production. Antimicrobial stewardship should therefore prioritize appropriate diagnosis, dose, duration, veterinary authorization and infection prevention, not an indiscriminate absence of treatment. Regulatory comparisons should distinguish treatment of confirmed illness, targeted preventive use under veterinary conditions and use unrelated to animal health.

Each arrow denotes a plausible link requiring data. In particular, the route from a resistant organism in an animal to a human clinical outcome cannot be inferred solely from antimicrobial sales or the size of a herd.

Processing plants, workers and food-safety externalities

Livestock health policy extends beyond the farm. Workers in transport, holding areas, slaughtering, processing and retail may face occupational hazards and unequal access to protective equipment and medical care. Food safety depends on ante-mortem and post-mortem inspection, hygienic processing, temperature controls, water quality, traceability and effective recall mechanisms. Contamination along these stages may occur even where farm-level infection indicators appear favorable.

The FAO/WHO Codex Alimentarius includes microbiological food hygiene standards, guidance for control of certain food hazards and provisions on veterinary-drug residues. International standards can facilitate trade, but they do not replace national legislation or create a uniform inspection capacity across countries. [7]

Investment in sanitation and laboratory facilities can protect consumers and preserve export market access. The distributional problem is how these costs are allocated among small farmers, larger processors, consumers and public budgets. A requirement that increases fixed compliance costs could encourage consolidation unless facilities, cooperative arrangements or technical assistance lower barriers to entry. Consolidation may, in turn, reshape prices, bargaining and surveillance incentives.

Global and regional exposure mechanisms

These are qualitative regional mechanisms, not measured rankings or claims that any region inherently presents higher biological risk. Trade exposure and public-health burden also depend on import reliance, veterinary capacity, healthcare access and the specificity of the agent. Country-level evidence is indispensable.

Governance across sectors

In August 2026, the Quadripartite announced the extension of its One Health Joint Plan of Action from the original 2022–2026 period through 2029. This is an institutional planning commitment, not an independently measured improvement in antimicrobial resistance outcomes. The extension allows countries to align public-health, environmental and animal-health efforts over a longer financing horizon. [8]

The 2025 WOAH annual publication, the 2025 WHO GLASS report and the 2026 UNEP guidance cover related but distinct analytical populations. Comparison is useful for identifying gaps, but their underlying measurements cannot simply be aggregated into a global 'One Health risk score'. [9, 6]

Comparing policy approaches without false equivalence

A country could adopt strict controls on non-therapeutic antimicrobial use, yet still face high resistance in hospitals because medical prescribing, sanitation and infection control differ. Another country could report a reduction in veterinary drug volume while experiencing a large animal disease outbreak unrelated to resistance. Both cases contradict the assumption that one policy indicator measures every dimension of biological security.

A serious evaluation uses repeated country or region observations before and after intervention, comparable control groups, consumption by antimicrobial class and species, independent microbiological surveillance and clinical outcomes. It should also test changes in animal welfare, mortality, farmer income and food prices. Changes in drug sales alone are insufficient: stocking decisions, reporting rates, species mix and substitution between products can affect the numerator.

Trade, finance and strategic dependence

Animal disease outbreaks can interrupt the movement of live animals and animal products even when they are not zoonotic. Dependence on a narrow set of processors or veterinary pharmaceutical inputs can amplify economic disruption. Small states reliant on a few export markets may suffer a sharper fiscal shock than larger diversified economies, although the effect depends on the actual product and market. Insurance, laboratory accreditation and traceability then become components of trade infrastructure.

Sanitary rules also have a geopolitical dimension: legitimate risk controls can protect consumers, while opaque or inconsistent application can be perceived as protectionism. Evaluating a trade measure requires identifying the declared hazard, evidentiary standard, proportionality and dispute-settlement regime. An import ban alone does not demonstrate intentional economic coercion.

Biosecurity policy should not be conflated with chemical or biological weapons accusations. Deliberate hostile action is a separate hypothesis requiring extraordinary evidence, professional investigation and clearly documented attribution. The OPCW's chemical verification architecture rests on treaty declarations and inspections; this institutional fact cannot be automatically transferred to the Biological Weapons Convention. [10]

The measurable research frontier

Three uncertainties should govern further comparisons. The first is attribution: which part of observed human resistance is causally linked to veterinary use in a particular system? The second is selection: are surveillance sites representative of national populations? The third is response: which mix of veterinary access, prevention, prescribing governance and public health delivers net benefits at a sustainable cost?

National datasets should include antimicrobial quantities with common denominators, farm-level infection and mortality outcomes, human clinical surveillance, food-chain sampling, waste management, trade disruptions and costs of enforcement. Where any component is missing, an analyst should describe the blind spot instead of filling it with estimates lacking transparent assumptions.

The economic value of livestock production and the need for disease prevention are not opposing absolutes. Their interaction depends on the capacity of institutions to identify risk, finance prevention, preserve necessary clinical treatment and prevent local health shocks from becoming long-lived economic and social losses.

References

1. WHO. Antimicrobial resistance: public-health fact sheet. Official source.
2. OPCW. Chemical Weapons Convention. Official source.
3. OPCW (2026). OPCW and UNODA cooperation on science and policy. Official source.
4. WHO (2025). Global antibiotic resistance surveillance report 2025. Official source.
5. WOAH (2025). Less antimicrobial use in animals: a win for everyone. Official source.
6. UNEP and Quadripartite (2026). Guidance on One Health integrated AMR surveillance. Official source.
7. FAO/WHO. Codex Alimentarius: institutional overview. Official source.
8. WOAH (2026). One Health Joint Plan of Action extended to 2029. Official source.
9. WOAH. Ninth annual report on antimicrobial agents intended for use in animals. Official source.
10. OPCW. Verification Division: official remit. Official source.